摘要
回顾性分析2018年12月至2021年5月接受肽受体放射性核素治疗(PRRT)的14例神经内分泌肿瘤患者资料,其中2例疾病进展,2例部分缓解,10例病情稳定。5例出现1~2级骨髓抑制,1例出现3级骨髓抑制,经对症治疗后恢复至2级。所有患者均未发现2级以上治疗相关性肾脏毒性。PRRT对于无法手术切除的转移性神经内分泌肿瘤有较好疗效,无明显不良反应。
The clinical data of 14 patients with neuroendocrine tumors who received Peptide Receptor Radionuclide Therapy(PRRT)from December 2018 to May 2021 were retrospectively analyzed.Among them,2 patients demonstrated proprogressive disease,2 patients had partial response,and 10 patients had stable disease.Grade 1-2 myelosuppression occurred in 5 patients.and 1 patient became grade 3 myelosuppression,which recovered to grade 2 after symptomatic treatment.No grade 2 or higher treatment-related renal toxicity was observed in any of the patients.PRRT is efficacy and no significant side effects for unresectable metastatic neuroendocrine tumors.
作者
姚晓晨
张川
臧士明
张朋俊
王俊
徐磊
俞飞
高晓洁
汤琪云
王峰
Yao Xiaochen;Zhang Chuan;Zang Shiming;Zhang Pengjun;Wang Jun;Xu Lei;Yu Fei;Gao Xiaojie;Tang Qiyun;Wang Feng(Department of Nuclear Medicine,Nanjing First Hospital,Nanjing Medical University,Nanjing 210006,China;Institution of Neuroendocrinology,Nanjing Medical University,Nanjing 210000,China)
出处
《中华医学杂志》
CAS
CSCD
北大核心
2022年第14期1034-1038,共5页
National Medical Journal of China
基金
南京市科技计划(201911042)
江苏省科技发展计划项目(BE2017612)。
